- POAI subsidiary Helomics helps oncologists individualize cancer treatment using patient-derived tumor models to improve outcomes
- Helomics’ tumor genomic and drug response database is one of the largest in the world with over 150,000 tumors across 137 cancer types
- Expected CAGR of 10.3% from 2018-2024 for oncology segment of precision medicine industry
The relationship between a patient and their cancer is personal: it’s specific, and it necessitates personalized treatment to be defeated effectively. Unfortunately, oncologists’ ability to personalize treatment for patients has largely been anything but, often resembling a trial-and-error method. This is largely because we have few targeted treatments or enough actionable data about how tumors with specific mutations respond to drugs. One innovator in the cancer research space, Predictive Oncology Inc. (NASDAQ: POAI), is working to change this dynamic by bringing its cutting-edge, AI-driven predictive models of tumor drug response and outcome to cancer research. These models predict how tumors respond to drugs and can be used for both clinical decision support, i.e. individualizing a patient’s therapy as well as research into new therapies, in partnership with the pharmaceutical and biotech industries.
With a mission to improve the standard of care for cancer patients, Helomics’ TruTumor(TM) platform harnesses the power of the patient’s own living tumor to address challenges oncologists often face when assessing patients and individualizing treatments. The clinically validated (in ovarian cancer) cell-based functional platform is in use today and profiles patient tumors, identifying key biomarkers and how the tumor responds to drugs and helps the oncologist determine a tailored therapy for that patient.
Helomics’ is building AI-driven predictive models by leveraging; a unique database of 150,000 tumor genomic and drug response profiles gathered from over 15 years of clinical testing using its TruTumor platform; access to over 15 years of outcome data from a national network of oncologists; plus a physical biobank of tumor samples that is being sequenced as part of its CancerQuest 2020 initiative (http://ibn.fm/B9mmE) to generate rich genomic profiles.
Along with subsidiaries TumorGenesis and Skyline Medical, POAI brings precision medicine to the treatment of cancer through collaborations with key players in the pharmaceutical, diagnostic and biotech industries. According to Mordor Intelligence Inc, oncology is expected to have the largest share of the precision medicine industry with estimated market dominance in excess of 30% over other precision medicine segments, and a CAGR of 10.3% from 2018 to 2024 (http://ibn.fm/8fqiH).
POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (PDx) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug repose to improve outcomes for the patients of today and tomorrow.
For more information, visit the company’s website at www.Predictive-Oncology.com
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI